老年III期非小细胞肺癌:放化疗联合较单纯放疗改善生存
基于美国国家癌症数据库2003-2014年≥70岁不可手术III期NSCLC患者,比较根治性放疗(n=5023)与根治性放化疗(n=18206)的总生存。倾向评分匹配前后,放化疗均与OS改善相关(匹配后HR=0.67,95%CI 0.64-0.70,p<0.001);序贯放化疗较同步放化疗死亡风险降低9%(HR=0.91,95%CI 0.85-0.96,p=0.002)。
要点
- 老年III期NSCLC根治性放化疗较单纯放疗显著改善总生存
- 序贯放化疗死亡风险较同步放化疗降低9%(HR=0.91)
- 该人群化疗与放疗最佳时序仍需前瞻性试验验证
核心结论
- 老年(≥70岁)III期不可手术NSCLC患者,根治性放化疗较根治性放疗有生存优势。
- 序贯放化疗优于同步放化疗,但最佳时序仍待前瞻性研究。
研究设计与样本
- 基于美国国家癌症数据库的比较效果研究,纳入2003-2014年诊断的≥70岁III期NSCLC未手术患者。
- 根治性放疗组n=5023(≥59.4 Gy),根治性放化疗组n=18206。
- 放化疗分为同步(放疗与化疗开始间隔≤30天)或序贯(化疗开始>30天后才开始放疗)。
- 采用Kaplan-Meier法和Cox比例风险回归,在倾向评分匹配前后比较OS。
主要发现
- 倾向评分匹配前,放化疗较放疗改善OS(HR=0.66,95%CI 0.64-0.68,p<0.001)。
- 倾向评分匹配后,放化疗较放疗改善OS(HR=0.67,95%CI 0.64-0.70,p<0.001)。
- 序贯放化疗较同步放化疗死亡风险降低9%(HR=0.91,95%CI 0.85-0.96,p=0.002)。
临床怎么用
- 对≥70岁III期不可手术NSCLC,应积极考虑根治性放化疗而非单纯放疗。
- 选择放化疗时序时可考虑序贯方案,但需结合前瞻性证据与个体情况。
局限性
- 为回顾性数据库比较效果研究,存在选择偏倚等混杂因素。
- 作者指出仍需前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Elderly patients account for the majority of lung cancer diagnoses but are poorly represented in clinical trials. We evaluated the overall survival (OS) of elderly patients with stage III NSCLC treated with definitive radiation compared with that of patients treated with definitive chemoradiation. METHODS: We conducted a comparative effectiveness study of radiation therapy versus chemoradiation in elderly (≥70 years old) patients with stage III NSCLC not treated surgically diagnosed from 2003 to 2014; the patients were identified by using the National Cancer Database. Two cohorts were evaluated: patients (n = 5023) treated with definitive radiation (≥59.4 Gy) and patients (n = 18,206) treated with definitive chemoradiation. Chemoradiation was further defined as concurrent (radiation and chemotherapy started within 30 days of each other) or sequential (radiation started >30 days after chemotherapy). We compared OS between the treatment groups by using the Kaplan-Meier method and Cox proportional hazards regression before and after propensity score matching (PSM). RESULTS: Treatment with chemoradiation was associated with improved OS versus that with radiation both before PSM (hazard ratio [HR] = 0.66, 95% confidence interval [CI]: 0.64-0.68, p < 0.001) and after PSM (HR = 0.67, 95% CI: 0.64-0.70, p < 0.001). Relative to concurrent chemoradiation, sequential chemoradiation was associated with a 9% reduction in the risk for death (HR = 0.91, 95% CI: 0.85-0.96, p = 0.002). CONCLUSIONS: We found that definitive chemoradiation resulted in a survival advantage compared with definitive radiation in elderly patients. Sequential chemotherapy and radiation was superior to concurrent chemoradiation. Although prospective trials are needed, this analysis suggests that chemoradiation should be strongly considered for elderly patients and the optimal sequencing of chemotherapy and radiation remains an unanswered question for this patient population.
引用
- Miller ED, Fisher JL, Haglund KE, et al. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29326090. doi:10.1016/j.jtho.2017.11.135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。